Endpoints NewsOriginal article
Beacon says gene therapy succeeds in key trial of rare eye disease XLRP
Phase 2positivePositive
AI Analysis
Summary
Beacon Therapeutics announced positive Phase trial results for its gene therapy targeting X-linked retinitis pigmentosa (XLRP), an indication where larger competitors including Johnson & Johnson and Biogen have previously failed.
Clinical Trial Data
Phase
2
Primary Endpoint
Met
Outcome Details
Gene therapy passed Phase trial for XLRP
Importance:7/10
Sentiment:
0.80
gene therapyrare diseaseophthalmologyclinical trial
Read the original article
Published by Endpoints News on September 21, 2026 6:00 AM